Dose-dependent Effect of Statin Therapy on Circulating CXCL12 Levels in Patients with Hyperlipidemia
Tóm tắt
HMG-CoA reductase inhibitors (statins) have pleiotropic effects that are independent of cholesterol-lowering, including a dose-dependent effect on angiogenesis. Angiogenesis plays a critical role both in vascularization of the chronically ischemic myocardium and in stabilization of atherosclerotic plaques. Chemokines, a family of structurally-related cytokine molecules, exert diverse biological functions including control of angiogenesis. The effect of statin therapy on angiogenic and angiostatic chemokines has not been evaluated extensively. We sought to test the hypothesis that, in subjects with hyperlipidemia, statin therapy influences plasma levels of angiogenic and angiostatic chemokines in a dose-dependent manner. We prospectively collected demographic, angiographic and laboratory data from subjects with a history of hyperlipidemia who were either untreated or on statin therapy. A peripheral blood sample was obtained for measurement of plasma angiogenic and angiostatic chemokines. Multivariable analysis using logistic regression was performed adjusting for the following variables: age, gender, prior myocardial infarction, and chronic administration of aspirin, clopidogrel, insulin, oral hypoglycemic agents, beta-blockers and calcium channel blockers. 168 patients on statin therapy (48 on low-dose, defined as <10mg atorvastatin-equivalent, and 120 on high-dose, defined as ≥10mg atorvastatin-equivalent dose) and 11 subjects from the same database who had a history of hyperlipidemia but who were not on statins were enrolled. There were no significant differences in baseline demographics, co-morbidities, lipid panels, other medications, or angiographic data between the groups. The angiogenic chemokines CXCL1 and CXCL12 levels were significantly different across the groups. Median levels of CXCL1 were highest in subjects not on statin therapy. Compared to subjects either not on statin therapy or on low-dose statins, those taking high-dose statins had lower median values of CXCL12 (2316 [2255–11071], vs 2362 [2016–10622], vs 2189 [1968–2705] pg/mL, p=0.042). On multivariate analysis, CXCL12 remained the only factor that was strongly and inversely associated with statin dose at the 95% level (p=0.011). Compared to no therapy or low-dose statin therapy, treatment with high-doses of HMG-CoA reductase inhibitors is associated with decreased circulating CXCL12 levels in subjects with hyperlipidemia, and CXCL12 is strongly and inversely associated with statin dose. Additional studies are needed to confirm this finding in other cohorts and to determine if high-dose statins affect angiogenesis in patients.
Tài liệu tham khảo
Davignon J: Beneficial cardiovascular effects of statins. Circulation 2004, 109(suppl III):II-39-III-43.
Weis M, Heeschen C, Glassford AJ, Cooke JP: Statins have biphasic effects on angiogenesis. Circulation 2002, 105: 739–745. 10.1161/hc0602.103393
Urbich C, Dernbach E, Zeiher AM, Dimmler S: Double-edged role of statins in angiogenesis signaling. Circ Res 2002, 90: 737–744. 10.1161/01.RES.0000014081.30867.F8
Skaletz-Rorowski A, Walsh K: Statin therapy and angiogenesis. Curr Opin Lipidol 2003, 14: 599–603. 10.1097/00041433-200312000-00008
Keeley EC, Moorman JR, Liu L, Gimple LW, Lipson LC, Ragosta M, Taylor AM, Lake DE, Burdick MD, Mehrad B, Strieter RM: Plasma chemokine levels are associated with the presence and extent of angiographic coronary collaterals in chronic ischemic heart disease. PLoS One 2011, 6(6):e21174. doi:10.1371/journal.pone.0021174
Jones P, Kafonek S, Laurora I, Hunninghake D: Comparative dose efficacy study of atorvastatin, versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (The Curves Study). Am J Cardiol 1998, 81: 582–587. 10.1016/S0002-9149(97)00965-X
Schroeter MR, Humboldt T, Schafer K, Konstantinides S: Rosuvastatin reduces atherosclerotic lesions and promotes progenitor cell mobilization and recruitment in apolipoprotein E knockout mice. Atherosclerosis 2009, 205: 63–73. 10.1016/j.atherosclerosis.2008.11.013
Waehre T, Damas JK, Gullestad L, Holm AM, Pedersen TR, Arnesen KE, Torsvik H, Froland SS, Semb AG, Aukrust P: Hydroxymethylglutaryl coenzyme A reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. J Am Coll Cardiol 2003, 41: 1460–1470. 10.1016/S0735-1097(03)00263-8
Karin N: The multiple faces of CXCL12 (SDF-1α) in the regulation of immunity during health and disease. J Leuk Biol 2010, 88: 463–473. 10.1189/jlb.0909602
Satoh K, Fukumoto Y, Nakano M, Sugimura K, Nawata J, Demachi J, Karibe A, Kagaya Y, Ischii N, Sugamura K, Shimokawa H: Statin ameliorates hypoxia-induced pulmonary hypertension associated with down-regulated stromal cell-derived factor-1. Cardiovasc Res 2009, 81: 226–234. 10.1093/cvr/cvn244
Shao H, Tan Y, Eton D, Yang Z, Uberti M, Li S, Schulick A, Yu H: Statin and stromal cell-derived factor-1 additively promote angiogenesis by enhancement of progenitor cells incorporation into new vessels. Stem Cells 2008, 26: 1376–1384. 10.1634/stemcells.2007-0785
Breland U, Halvorsen B, Hol J, Oie E, Paulsson-Berne G, Yndestad A, Smith C, Otterdal K, Hedin U, Waehre T, Sandberg W, Froland S, Haraldsen G, Gullestad L, Damas J, Hansson G, Aukrust P: A potential role of the CXC chemokine GROα in atherosclerosis and plaque destabilization: downregulatory effects of statins. Arterioscler Thromb Vasc Biol 2008, 28: 1005–1011. 10.1161/ATVBAHA.108.162305
Schutt RC, Burdick MD, Strieter RM, Mehrad B, Keeley EC: Plasma CXCL12 Levels as a Predictor of Future Stroke. Stroke 2012. in press in press